title: Combining censored and uncensored data in a U-statistic: design and sample size implications for cell therapy research.
abstract: The assumptions that anchor large clinical trials are rooted in smaller, Phase II studies. In addition to specifying the target population, intervention delivery, and patient follow-up duration, physician-scientists who design these Phase II studies must select the appropriate response variables (endpoints). However, endpoint measures can be problematic. If the endpoint assesses the change in a continuous measure over time, then the occurrence of an intervening significant clinical event (SCE), such as death, can preclude the follow-up measurement. Finally, the ideal continuous endpoint measurement may be contraindicated in a fraction of the study patients, a change that requires a less precise substitution in this subset of participants.A score function that is based on the U-statistic can address these issues of 1) intercurrent SCE's and 2) response variable ascertainments that use different measurements of different precision. The scoring statistic is easy to apply, clinically relevant, and provides flexibility for the investigators' prospective design decisions. Sample size and power formulations for this statistic are provided as functions of clinical event rates and effect size estimates that are easy for investigators to identify and discuss. Examples are provided from current cardiovascular cell therapy research.
authors.affiliation: University of Texas Health Science Center at Houston, Texas, USA.
authors.forename: Lemuel A
authors.initials: LA
authors.lastname: Moyé
authors.forename: Dejian
authors.initials: D
authors.lastname: Lai
authors.forename: Kaiyan
authors.initials: K
authors.lastname: Jing
authors.forename: Mary Sarah
authors.initials: MS
authors.lastname: Baraniuk
authors.forename: Minjung
authors.initials: M
authors.lastname: Kwak
authors.forename: Marc S
authors.initials: MS
authors.lastname: Penn
authors.forename: Colon O
authors.initials: CO
authors.lastname: Wu
mesh_terms: D056808:Biostatistics / Q000379:methods*; D017322:Clinical Trials, Phase II as Topic; D023381:Endpoint Determination / Q000706:statistics & numerical data*; D006801:Humans; D012107:Research Design / Q000706:statistics & numerical data; D018401:Sample Size; D018709:Statistics, Nonparametric; D057905:Stem Cell Research